Cargando…

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

AIMS. Galectin-3 is an emerging biomarker which has been studied in relatively small heart failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base-line galectin-3 in a large HF cohort, with preserved and reduced left ventricular ejection fraction (lvef), and comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boer, Rudolf A, Lok, Dirk J A, Jaarsma, Tiny, van der Meer, Peter, Voors, Adriaan A, Hillege, Hans L, van Veldhuisen, Dirk J
Formato:	Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028573/ https://www.ncbi.nlm.nih.gov/pubmed/21189092 http://dx.doi.org/10.3109/07853890.2010.538080

Ejemplares similares

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
por: Tromp, Jasper, et al.
Publicado: (2017)

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides
por: Meijers, W. C., et al.
Publicado: (2016)

Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction
por: Schroten, Nicolas F., et al.
Publicado: (2015)

Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations
por: Vegter, Eline L., et al.
Publicado: (2017)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Renal dysfunction is associated with shorter telomere length in heart failure
por: Wong, Liza S. M., et al.
Publicado: (2009)

Galectin-3 in Cardiac Remodeling and Heart Failure
por: de Boer, Rudolf A., et al.
Publicado: (2010)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Klaassen, Sebastiaan HC, et al.
Publicado: (2020)

Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure
por: de Boer, Rudolf A., et al.
Publicado: (2012)

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis
por: van den Berg, Maarten P, et al.
Publicado: (2019)

Current and novel renal biomarkers in heart failure
por: Damman, Kevin, et al.
Publicado: (2011)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
por: Lok, Dirk J. A., et al.
Publicado: (2010)

Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018)

Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
por: Chia, Yook Chin, et al.
Publicado: (2021)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
por: Nauta, J. F., et al.
Publicado: (2021)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure
por: Linssen, G. C. M., et al.
Publicado: (2018)

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
por: Shi, Yujiao, et al.
Publicado: (2022)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
por: Wintrich, Jan, et al.
Publicado: (2020)

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
por: Withaar, Coenraad, et al.
Publicado: (2020)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction
por: Jiang, Jing, et al.
Publicado: (2022)

Treatment of heart failure with ACE inhibitors and beta-blockers: What is next? Aldosterone receptor antagonists?
por: van der Horst, Iwan C. C., et al.
Publicado: (2007)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure
por: Tromp, Jasper, et al.
Publicado: (2018)

Prevalence and Incidence of Atrial Fibrillation in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: (Additive) Value of Implantable Loop Recorders
por: Gorter, Thomas M., et al.
Publicado: (2023)

Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study
por: van Veldhuisen, Dirk J., et al.
Publicado: (2020)

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
por: Binnenmars, S. Heleen, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
por: Trippel, Tobias Daniel, et al.
Publicado: (2021)

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
por: Kanukurti, Jyothirmayi, et al.
Publicado: (2020)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Prognostic value of galectin-3, a novel marker of fibrosis
por: Lok, Dirk J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_eeaioiih2dhpvtn6k6a7mkuija